Crosspoint Capital Strategies’s Jazz Pharmaceuticals JAZZ Stock Holding History

Crosspoint Capital Strategies’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-142	Closed	-$23K	–	488
2015 Q4	$23K	Buy	+142	New	+$19.7K	0.01%	564
2015 Q3	–	Sell	-120	Closed	-$21K	–	836
2015 Q2	$21K	Buy	+120	New	+$21.6K	0.01%	426
2015 Q1	–	Sell	-657	Closed	-$108K	–	629
2014 Q4	$108K	Buy	657 +177	+37%	+$29.4K	0.04%	278
2014 Q3	$77K	Hold	480	–	–	0.06%	182
2014 Q2	$66K	Sell	480 -38	-7%	-$5.27K	0.02%	220
2014 Q1	$74K	Sell	518 -33,819	-98%	-$5.09M	0.03%	222
2013 Q4	$5.52M	Buy	+34,337	New	+$3.55M	1.84%	29

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Crosspoint Capital Strategies's JAZZ Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2016, closing a stake of 142 shares — an estimated $23K sold.

Crosspoint Capital Strategies first reported a position in JAZZ in Q4 2013 and held it in 7 quarters. The position peaked at $5.52M in Q4 2013. 339 funds tracked by Wall St. Rank hold JAZZ as of Q1 2016.

Crosspoint Capital Strategies reported no remaining Jazz Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Crosspoint Capital Strategies sold 142 Jazz Pharmaceuticals shares in Q1 2016, an estimated $23K.
Crosspoint Capital Strategies first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 7 quarters.
Crosspoint Capital Strategies's Jazz Pharmaceuticals position peaked at $5.52M in Q4 2013.
339 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.